Legal Representation
Attorney
Deborah L. Corpus
USPTO Deadlines
Next Deadline
1387 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-08-22)
Due Date
August 22, 2029
Grace Period Ends
February 22, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
25 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Dec 6, 2024 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| Dec 6, 2024 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Dec 6, 2024 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Dec 6, 2024 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Aug 22, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Aug 22, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jul 19, 2023 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jul 18, 2023 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jul 17, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 17, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| May 17, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Apr 27, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Apr 27, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Dec 20, 2022 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 25, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 25, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 5, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 19, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 25, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 25, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 25, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 25, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 22, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 18, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 15, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for animals for regulating the immune system and treating cancer; pharmaceutical preparations, namely, immunomodulators; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the treatment of cells for regulating the immune system and treating cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; biopharmaceutical products for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory diseases; stem cells for medical purposes; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of immune system related diseases and disorders
First Use Anywhere:
Aug 5, 2019
First Use in Commerce:
Aug 5, 2019
Class 042
Development of cell therapy products; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; scientific research for medical purposes; medical and pharmacological research services; medical research services; development of biotechnology products; biotechnological research; cell separation research services; technological research in the field of cell therapy, medicine, pharmacology, biotechnology
First Use Anywhere:
Mar 5, 2019
First Use in Commerce:
Mar 5, 2019
Additional Information
Pseudo Mark
NATURAL KILLER MAXIMIZING
Classification
International Classes
005
042